nbm-bmx
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 16, 2018 (NCT03726294)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Catenin beta-1ANTAGONIST
CTNNB1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06012695 | Phase 1/Phase 2 (Phase 2) | Aug 11, 2023 | NatureWise Biotech & Medicals Corporation |
| NCT03808870 | Phase 1 | Feb 21, 2019 | NatureWise Biotech & Medicals Corporation |
| NCT03726294 | Phase 1 | Oct 16, 2018 | NatureWise Biotech & Medicals Corporation, NEXT Oncology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NatureWise Biotech & Medicals Corporation | For profit | 3 | 3 | 2 | 2018 |
| NEXT Oncology | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1